RxDoctor Payments DataLook up a doctor →

Marguerite McDonald, MD

Ophthalmology · Oceanside, NYNPI 1356348452

Payments from drug & device makers

$931,401in general payments, 2019–2025

Across 1,231 payments — averaging $756.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$205K
  • AbbVie$122K
  • Oculus, Inc.$121K
  • Sun Pharmaceutical Industries Inc.$94K
  • Alcon$77K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$39K
  • plus $273K from 38 others

What the payments were for

  • Consulting fees$473,05053%
  • Speaking & faculty fees$341,29438%
  • Travel & lodging$39,2714%
  • Food & beverage$38,7154%
  • Education$3050%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$931,401 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.

See all ophthalmology providers in New York

Medicare billing

Part B allowed, 2024
$349,437
Medicare patients
1,097
Services billed
4,483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj35$1,309,947
XiidraLifitegrast477$599,720
RestasisCyclosporine427$551,202
MieboPerfluorohexyloctane/Pf151$152,891
Cyclosporine153$75,098
Bepotastine Besilate265$48,010
TyrvayaVarenicline Tartrate60$38,651
ErythromycinErythromycin Base875$31,940
Restasis MultidoseCyclosporine32$30,116
XdemvyLotilaner13$23,380
RhopressaNetarsudil Mesylate40$22,093
LumiganBimatoprost30$15,357
CequaCyclosporine15$14,906
ZirganGanciclovir20$9,121
SimbrinzaBrinzolamide/Brimonidine Tart35$9,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$33,208$1,309,94735 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Zirgan, Vyzulta$205,072$767,927662 claims
AbbVieRestasis, Restasis Multidose, Lumigan$122,437$596,675489 claims
Oyster Point Pharma, Inc.Tyrvaya$15,824$38,65160 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$5,210$23,38013 claims
Aerie Pharmaceuticals, Inc.Rhopressa$36$22,09340 claims
Sun Pharmaceutical Industries Inc.Cequa$93,590$14,90615 claims
AlconSimbrinza$76,920$9,03435 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCBepreve$39,458$4,02615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.

Other ophthalmology in Oceanside

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →